Vectivbio Holding Ag Stock Price, News & Analysis

VectivBio has received FDA clearance for its IND application to study apraglutide in a clinical trial targeting acute graft-versus-host disease (aGVHD). The Phase 2 study, titled STARGAZE, will dose its first patient in 1Q 2022, with interim results expected in 2H 2022. Previously, apraglutide gained orphan drug status, highlighting its potential as a non-immunosuppressive treatment for aGVHD, which affects many post-stem cell transplant patients. The drug aims to protect intestinal cells, addressing a critical unmet need in the treatment landscape.

VectivBio has announced the successful acquisition of Comet Therapeutics, enhancing its pipeline for treating severe rare Inherited Metabolic Diseases (IMDs). The proprietary CoMET platform targets critical cellular dysfunctions with a stabilized CoA precursor backbone to treat previously untreatable conditions affecting over 75,000 people in the US and Europe. The first candidate, VB-1197, will focus on severe organic acidemias, aiming to start Phase 1 trials within 18 months.

VectivBio Holding AG (Nasdaq: VECT) has announced a virtual R&D Day scheduled for September 21, 2021, from 10 a.m. to 12 p.m. EDT. The event will focus on the company's late-stage clinical candidate, apraglutide, aimed at treating Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Graft Versus Host Disease (GVHD). Notable speakers include Dr. Kishore Iyer and Dr. Robert Zeiser. VectivBio will also participate in the SVB Leerink CybeRX Series event on September 23, 2021. The webcast will be available through their website, with registration already open.

VectivBio Holding AG (Nasdaq: VECT) announced the appointment of Scott Applebaum as Chief Legal Officer & Corporate Secretary, effective September 8, 2021. With over 20 years in the biopharmaceutical industry, Applebaum is expected to enhance VectivBio's legal, regulatory, and operational frameworks. His experience includes previous roles at Trevena and Shire, crucial in obtaining FDA approvals. This leadership change aims to support the advancement of VectivBio’s Phase 3 trial of apraglutide for Short Bowel Syndrome and further pipeline expansion.

VectivBio Holding AG (Nasdaq: VECT) announced on September 3, 2021, the election of Paul R. Carter and Dr. Murray W. Stewart to its Board of Directors. Carter, a seasoned executive with over a decade at Gilead Sciences, brings extensive experience in commercialization. Dr. Stewart has a strong background in drug development, previously working as the Chief Medical Officer at Rhythm Pharmaceuticals. VectivBio is focused on developing treatments for severe rare conditions, with its lead product candidate, apraglutide, currently in a Phase 3 clinical trial for short bowel syndrome.

VectivBio announced its acquisition of Comet Therapeutics, enhancing its rare disease pipeline focused on Inherited Metabolic Diseases (IMDs). The proprietary CoMET platform targets energy metabolism disorders affecting over 75,000 patients in the US and Europe. The transaction, approved by both companies’ boards, involves equity and cash payments, including milestones. The acquisition aims to develop a pipeline of medicines that restore cellular metabolism, addressing severe conditions like methylmalonic acidemia. An R&D Day is scheduled for September 21, 2021, to discuss ongoing projects including apraglutide.

VectivBio Holding AG (Nasdaq: VECT) announced its Extraordinary General Meeting scheduled for September 2, 2021. The sole agenda item is the election of Paul R. Carter and Dr. Murray W. Stewart to the Board of Directors. Due to COVID-19, the meeting will not allow personal attendance; shareholders must use an independent proxy for representation. VectivBio is focused on developing treatments for severe rare conditions, with apraglutide as its lead candidate currently in a Phase 3 trial for short bowel syndrome.

VectivBio Holding AG (Nasdaq: VECT) has nominated Paul R. Carter and Murray W. Stewart, DM, FRCP, for election as Independent Non-Executive Directors at an Extraordinary General Meeting on September 2, 2021. Both nominees bring over two decades of experience in clinical, regulatory, and commercial management within the biopharmaceutical sector. The company, focusing on innovative treatments for severe rare conditions, is in the Phase 3 trial of its lead drug candidate, apraglutide, aimed at addressing short bowel syndrome with intestinal failure.

VectivBio Holding AG (Nasdaq: VECT) announced that the FDA granted orphan drug designation to apraglutide, a long-acting GLP-2 analog, for preventing acute graft-versus-host disease (aGVHD). This designation is significant for treating rare gastrointestinal diseases. VectivBio plans to initiate a Phase 2 trial in the first quarter of 2022 to assess apraglutide's potential in treating aGVHD. The FDA's orphan drug designation provides benefits such as seven years of market exclusivity and tax credits. Apraglutide is also evaluated for other indications, including treatment for short bowel syndrome.